| 1. |
- Augustsson, Katarina, et al.
(författare)
-
Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney : a population-based study
- 1999
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 353:9154, s. 703-707
-
Tidskriftsartikel (refereegranskat)abstract
- Background Heterocyclic amines formed in cooked meat and fish are carcinogenic in animal models and form DNA adducts in human beings. We undertook a study to assess whether these substances are related to the risks of cancer in the large bowel and urinary tract. Methods In a population-based case-control study, cases were identified from the Swedish cancer registry. Controls were randomly selected from the population register. Information on intake of various foods and was assessed by questionnaire, with photographs of foods cooked at various temperatures. We measured the content of heterocyclic amines in foods cooked under these conditions. Findings Information was retrieved from 553 controls, 352 cases of colon cancer, 249 cases of rectal cancer, 273 cases of bladder cancer, and 138 cases of kidney cancer. The response rate was 80% for controls and 70% for cases. The estimated daily median intake of heterocyclic amines was 77 ng for controls, and 66 ng, 63 ng, 96 ng, and 84 ng for cases with cancer of the colon, rectum, bladder, and kidney, respectively. The relative risk for the intake of heterocyclic amines (highest vs lowest quintile) was 0.6 (95% CI 0.4-1.0) for colon cancer, 0.7 (0.4-1.1) for rectal cancer, 1.2 (0.7-2.1) for bladder cancer, and 1.0 (0.5-1.9) for kidney cancer. Seven cases, but no controls, had an estimated daily intake of heterocyclic amines above 1900 ng. Interpretation Intake of heterocyclic amines, within the usual dietary range in this study population, is unlikely to increase the incidence of cancer in the colon, rectum, bladder, or kidney. For daily intakes above 1900 ng, our data are consistent with human carcinogenicity, but the precision was extremely low.
|
|
| 2. |
- Békássy, Albert, et al.
(författare)
-
Erwinase-induced pancreatitis
- 1992
-
Ingår i: The Lancet. - 1474-547X. ; 340:8834-8835, s. 1552-1553
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
|
|
| 4. |
- Björkstén, B
(författare)
-
Allergy priming early in life.
- 1999
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 353, s. 167-168
-
Tidskriftsartikel (refereegranskat)
|
|
| 5. |
- Bogg, Lennart, 1948-
(författare)
-
Health insurance in rural Africa
- 1995
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 345:8948, s. 521-522
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
- Bogg, Lennart, et al.
(författare)
-
Tuberculosis control in China
- 1996
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 347:9016, s. 1702-1702
-
Tidskriftsartikel (refereegranskat)
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- García Rodrígues, LA, et al.
(författare)
-
Ocular safety of antiulcer drugs.
- 1995
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 345:8956, s. 1059-1060
-
Tidskriftsartikel (refereegranskat)
|
|
| 10. |
- Gärdlund, B, et al.
(författare)
-
Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group.
- 1996
-
Ingår i: The Lancet. - : Elsevier BV. - 0140-6736 .- 1474-547X. ; 347:9012, s. 1357-61
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Fatal pulmonary embolism and other thromboembolic complications are common in hospital inpatients. However, there is little evidence on the routine use of pharmacological thromboprophylaxis in non-surgical patients. We assessed the efficacy and safety of low-dose heparin in the prevention of hospital-acquired, clinically relevant, fatal pulmonary embolism in patients with infectious diseases.METHODS: Our study used the postrandomisation consent design. 19,751 consecutive patients, aged 55 years or older, admitted to departments of infectious diseases in six Swedish hospitals, were screened for inclusion in the randomised, controlled, unblinded, multicentre trial. Of the eligible patients, 5776 were assigned subcutaneous standard heparin (5000 IU every 12 h) until hospital discharge or for a maximum of 3 weeks; 5917 were assigned no prophylactic treatment (control group). We sought consent only from the heparin group. Follow-up was for 3 weeks after discharge from hospital or for a maximum of 60 days from randomisation. The primary endpoint was necropsy-verified pulmonary embolism of predefined clinical relevance.FINDINGS: By intention-to-treat analysis mortality was similar in the heparin and control groups (5.3 vs 5.6%, p = 0.39) and the median time from admission to death was 16 days in both groups (IQR 8-31 vs 6-28 days). Necropsy-verified pulmonary embolism occurred in 15 heparin-treated and 16 control-group patients. There was a significant difference between heparin and control groups in median time from randomisation to fatal pulmonary embolism (28 [24-36] vs 12.5 [10-20] days, p = 0.007). This difference corresponds to the duration of heparin prophylaxis. Non-fatal thromboembolic complications occurred in more of the control than of the heparin group (116 vs 70, p = 0.0012).INTERPRETATION: Our findings do not support the routine use of heparin prophylaxis for 3 weeks or less in large groups of non-surgical patients. Further studies are needed to investigate whether heparin prophylaxis of longer duration may prevent fatal pulmonary embolism.
|
|
